このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

プレバイオティクスと食物繊維介入が睡眠、腸内細菌叢、認知機能、ストレスに及ぼす影響の評価

2026年11月9日 更新者:Northumbria University

Evaluating the Effects of Nutritional Interventions on Sleep, the Gut Microbiome, Cognition, and Stress

This will be a double-blind, placebo-controlled, parallel-group trial. Participants who are poor sleepers will be randomised to receive one of two investigational supplements, or a placebo control supplement, over a 28-day period. At baseline and following 28 days of consumption, sleep quality, gut microbiome profiles, cognitive performance, and mood will be assessed. Sleep outcome measures will also be assessed throughout the supplementation period to monitor the time course of any observed changes. A final data set of at least 66 participants is expected.

調査の概要

状態

積極的、募集していない

条件

介入・治療

詳細な説明

This will be a double-blind, placebo-controlled, parallel-group trial. Participants who are poor sleepers will be randomised to receive one of two investigational supplements, or a placebo control supplement, over a 28-day period. At baseline and following 28 days of consumption, sleep quality, gut microbiome profiles, cognitive performance, and mood will be assessed. Sleep outcome measures will also be assessed throughout the supplementation period to monitor the time course of any observed changes. A final data set of at least 66 participants is expected.

Interested participants will initially be scheduled to complete a screening telephone call with the researcher. Here, electronic informed consent will first be provided by the participant, by accessing a pre-emailed link to the Qualtrics survey platform, to an account which is hosted by Northumbria University. Once consent is obtained, the participant will confirm that they do not meet any of the study exclusion criteria, and will complete the SDS-CL checklist with the researcher, over the phone. If any clinical thresholds are met, participants will be invited to a separate clinical interview (again via phonecall) with Professor Jason Ellis, employing the International Classification of Sleep Disorders (ICSD-3) criteria, to determine elligibility.

If participants progress to enrolment, they will be invited to attend a lab-based training/screening session (protocol day -7) at Northumbria University. Here, hard and wet-signed (by both the participant and the researcher) consent forms will be completed and stored on site. Participants will then be familiarised with the study protocol and procedures. Participants will also be trained on the cognitive tasks. During the following 7 nights (Protocol days -7 to -1), participants will monitor their sleep and complete the daily Sleep Diary each morning. During this week, they will also drop off their pre-dose baseline stool sample at a remote drop-off location at Northumbria University.

Seven days following the lab-based screening visit (Supplement day 1, Protocol day 0), participants will attend the laboratory for their acute visit. Here, a pre-dose baseline sample of saliva and a single blood sample will be taken (for Alpha Amylase, Cortisol, Serotonin and Melatonin), and Blood Pressure, Heart Rate, Body Mass Index, and Waist-to-Hip Ratio will be measured. Participants will complete the Intake24 dietary assessment, and gastrointestinal symptoms questionnaires, as well as the Pittsburgh Sleep Quality Index (PSQI), State-Trait Anxiety Inventory (STAI), and Depression, Anxiety and Stress Scale - 21 Items (DASS-21). The cognitive task battery will additionally be completed.

After completing these measures, participants will receive instructions on the next phase of the trial. From that night, participants will consume their first dose of the investigational supplement (noting the time in their treatyment diary) 4 hours before their normal bed-time. They will monitor their sleep overnight. The following morning (supplementation day 2, protocol day 1), participants will complete their Sleep Diary. Participants will follow this procedure for the following 27 days. At some point during Protocol (Days 12-18), participants will return to Northumbria University to drop-off their interim stool sample.

On Protocol day 28, participants will return to the lab for the chronic testing visit. All of the outcome measures assessed during the acute lab visit (Protocol day 0) will be repeated here. At the end of the session, participants will be debriefed, and their participation payment arranged. At some point during Protocol (Days 27-33) participants will return to Northumbria University to drop-off their chronic stool sample.

研究の種類

介入

入学 (実際)

69

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

      • Newcastle upon Tyne、イギリス
        • Northumbria University- Northumbria Sleep center and NUTRAN

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

25年~65年 (大人、高齢者)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

説明

INCLUSION CRITERIA

  • Participants must self-assess themselves as being in good health.
  • Aged 25 to 60 years at the time of randomisation
  • Fluent in English
  • Identify as a 'poor sleeper' as defined subjectively (i.e. poor sleep quality, unrefreshing sleep) and a total score of >5 on the Pittsburgh Sleep Quality Index (PSQI).

EXCLUSION CRITERIA

  • Member of own household currently participating in this trial
  • Evidence of current or recent sleep disorders (e.g. sleep apnoea, insomnia, circadian rhythm disorders), taking any medication which exerts sedative effects, affects the CNS and/or sleep, or be currently unwell with any illness that affects sleep (i.e. disorders of the CNS). An initial screening for sleep disorders will be conducted using the Sleep Disorders Symptom Checklist-25 (SDS-CL; Klingman et al., 2017). If a participant reports positively to any of the 25 questions in terms of being affected for three nights per week, or more, this will be followed up using a clinical interview according to the International Classification of Sleep Disorders (ICSD-3) to exclude on the basis of a sleep disorder
  • History of seizures or epilepsy
  • Shift working or have a history of shift work within the previous six months
  • Currently, or within the previous 8 weeks, consuming any nutritional supplements.
  • Participation in any other intervention research trials
  • Sleeping at a location other than their usual residence more than two nights per week during participation
  • Travel across multiple time zones within the last three months or have planned travel across multiple time zones during the study
  • Current or recent mood disturbances or Axis I disorders (descriptions will be given)
  • Current misuse of alcohol and/or drugs
  • Current smoker
  • Recent (within the last 12 weeks) infection and/or use of antibiotic medication
  • Pregnant, seeking to become pregnant or lactating
  • Those using (including within the last 2 weeks) proton-pump inhibitors

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:他の
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:トリプル

武器と介入

参加者グループ / アーム
介入・治療
実験的:Arm 1

Participants will be randomly allocated to consume investigational supplement (1 of 2 proprietary 'active' compositions) for 28 days.

A proprietary orally administered dietary supplement consisting of standardized ingredients.

実験的:Arm 2

Participants will be randomly allocated to consume investigational supplement (1 of 2 proprietary 'active' compositions) for 28 days.

A proprietary orally administered dietary supplement consisting of standardized ingredients.

プラセボコンパレーター:Control

Participants will be randomly allocated to consume control supplement for 28 days.

Flavored vehicle

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Sleep Efficiency (SE)
時間枠:Change from Baseline to end of supplementation period at 28 days

Sleep efficiency (SE), commonly defined as the ratio of total sleep time (TST) to time in bed (TIB), will be reported as a percentage of time in bed.

Change from Baseline to end of supplementation period at 28 days

二次結果の測定

結果測定
メジャーの説明
時間枠
Actigraphy - Sleep onset latency
時間枠:Change from baseline following 28 days of supplement consumption

recorded minutes taken from intention to sleep to sleep initiation

Change from baseline following 28 days of supplement consumption
Actigraphy - Sleep efficiency
時間枠:Change from baseline following 28 days of supplement consumption

ratio of the total time spent asleep (total sleep time) in a night compared to the total amount of time spent in bed (percentage)

Change from baseline following 28 days of supplement consumption
Actigraphy - Number of awakenings
時間枠:Change from baseline following 28 days of supplement consumption

recorded number of awakenings during entire sleep period

Change from baseline following 28 days of supplement consumption
Actigraphy - Wake after sleep onset (WASO)
時間枠:Change from baseline following 28 days of supplement consumption

recorded minutes awake during the entire sleep period following sleep onset

Change from baseline following 28 days of supplement consumption
COMPASS global performance measures
時間枠:Change from baseline following 28 days of supplement consumption

Speed of performance, and accuracy of performance measured by Computerised Mental Performance Assessment System (COMPASS, Northumbria University)

Change from baseline following 28 days of supplement consumption
Pittsburgh Sleep Quality Index (PSQI)
時間枠:Change from baseline following 28 days of supplement consumption

Pittsburgh Sleep Quality Index (PSQI): Total Score. The PSQI is a validated self-rating instrument assessing aspects of sleep quality.Minimum score 0 (better); maximum score 21 (worse) < or = 5 associated with good sleep quality; > 5 associated with poor sleep quality.

Change from baseline following 28 days of supplement consumption
Depression, Anxiety and Stress Scale - 21 Items (DASS-21)
時間枠:Change from baseline following 28 days of supplement consumption

A 21-item measure of mood over the previous week (each item is rated on scale from 0-3). Scoring creates 3 component scores: depression, anxiety and stress (each on a scale of 0-21) with higher scores indicating higher symptomology. Cut-off scores, according to each set of symptoms, are available (normal, mild, moderate, severe and extremely severe) or total scores can be derived by multiplying the sum of all three component scores by 2.

Change from baseline following 28 days of supplement consumption
State-Trait Anxiety Inventory (STAI)
時間枠:Change from baseline following 28 days of supplement consumption

A 40-item measure of current and general anxiety levels. Each item is rated on a scale from 1-4. Scoring creates two components: state anxiety (20 items) and trait anxiety (20 items), with a range for each between 20-80. Following transformation through reversed coding, higher scores indicate higher levels of anxiety

Change from baseline following 28 days of supplement consumption
Actigraphy - Total sleep time
時間枠:Change from baseline following 28 days of supplement consumption

recorded minutes asleep over entire sleep period

Change from baseline following 28 days of supplement consumption
Sleep Diary - Total sleep time
時間枠:Change from baseline following 28 days of supplement consumption

recorded minutes asleep over entire sleep period

Change from baseline following 28 days of supplement consumption
Sleep Diary - Sleep onset latency
時間枠:Change from baseline following 28 days of supplement consumption

logged minutes taken from intention to sleep to sleep initiation

Change from baseline following 28 days of supplement consumption
Sleep Diary - Sleep efficiency
時間枠:Change from baseline following 28 days of supplement consumption

ratio of the total time spent asleep (total sleep time) in a night compared to the total amount of time spent in bed (percentage)

Change from baseline following 28 days of supplement consumption
Sleep Diary - Number of awakenings
時間枠:Change from baseline following 28 days of supplement consumption

logged number of awakenings during entire sleep period

Change from baseline following 28 days of supplement consumption
Sleep Diary - Wake after sleep onset (WASO)
時間枠:Change from baseline following 28 days of supplement consumption

logged minutes awake during the entire sleep period following sleep onset

Change from baseline following 28 days of supplement consumption

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Professor Jason Ellis, PhD、Northumbria University

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年4月1日

一次修了 (推定)

2026年12月1日

研究の完了 (推定)

2027年4月1日

試験登録日

最初に提出

2026年1月19日

QC基準を満たした最初の提出物

2026年1月19日

最初の投稿 (実際)

2026年1月27日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月13日

QC基準を満たした最後の更新が送信されました

2026年11月9日

最終確認日

2026年2月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 000000

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。